Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | GNAO1 | P09471 | 11/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 10/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 10/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LSS | P48449 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25787123 | 1.00 | CYP1A2 (0.56) | CYP1A2GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL11633879 | 0.96 | GNAO1 (0.54) | CYP1A2GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL27482076 | 0.96 | GNAO1 (0.54) | CYP1A2GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL27497177 | 0.96 | GNAO1 (0.54) | CYP1A2GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL27496834 | 0.96 | GNAO1 (0.54) | CYP1A2GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL25247041 | 0.96 | GNAO1 (0.54) | CYP1A2GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL465210 | 0.96 | GNAO1 (0.54) | CYP1A2GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL27496492 | 0.96 | GNAO1 (0.54) | CYP1A2GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL27496493 | 0.96 | GNAO1 (0.54) | CYP1A2GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL465213 | 0.94 | CYP1A2 (0.61) | CYP1A2GNAO1GNAI3GNAI1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | CYP1A2 164/4885GNAO1 1106/4885GNAI3 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.